Use of a combination of (a) a prostaglandin compound (PG) represented by formula (II): in which L and M are hydrogen, hydroxy, halogen, linear or branched C1-6 alkyl, linear (C1-6 linear) hydroxyalkyl or branched), linear or branched C1-6 alkanoyloxy or oxo, wherein at least one of L and M is a different group of hydrogen, and the five-membered ring may have one or more double bonds； A is -CH3, or -CH2OH, -COCH2OH-COOH or a salt, ether, ester or amide thereof； B is a single bond, -CH2-CH2-, -CH = CH-, -CºC-, -CH2-CH2-CH2-, -CH = CH-CH2-, -CH2-CH = CH-, CºC-CH2- or -CH2-C-； Z is or a single bond in which R4 and R5 are hydrogen, hydroxy, halogen, linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy or hydroxyalkyl (C1-6 linear or branched), in which R4 and R5 are not hydroxy and C1-6 linear or branched alkoxy at the same time； X1 and X2 are hydrogen, linear or branched C1-6 alkyl or halogen； R1 is a saturated or unsaturated linear or branched chain bivalent hydrocarbon group, having 1 to 14 carbon atoms, which is unsubstituted or substituted by a halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at less one of the carbon atoms in the hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur； R2 is a straight or branched C1-6 alkylene single bond or alkylene； and R3 is linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy, linear or branched C1-6 alkanoyloxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic group -oxy, provided that one of X1 and X2 is substituted by halogen and / or Z is C = O and (b) a proton pump inhibitor in association with a pharmaceutically acceptable excipient for the manufacture of a pharmaceutical composition for the treatment of gastrointestinal disorders.Uso de una combinación de (a) un compuesto de prostaglandina (PG) representado por la fórmula (II): en la que L y M son hidrógeno, hidroxi, halógeno, alquilo C1-6 lineal o ramificado, hidroxialquilo (C1-6 lineal o
